vs
Side-by-side financial comparison of GAXOS.AI INC. (GXAI) and Q32 Bio Inc. (QTTB). Click either name above to swap in a different company.
Q32 Bio Inc. is the larger business by last-quarter revenue ($1.9M vs $1.2M, roughly 1.6× GAXOS.AI INC.). Q32 Bio Inc. runs the higher net margin — 2991.2% vs -77.2%, a 3068.4% gap on every dollar of revenue.
Q32 Bio Inc. is a clinical-stage biotechnology company focused on developing targeted antibody-based immunotherapies for autoimmune disorders, inflammatory conditions and rare immunological diseases with unmet medical needs, operating primarily across North America and European markets.
GXAI vs QTTB — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.2M | $1.9M |
| Net Profit | $-957.9K | $57.7M |
| Gross Margin | — | — |
| Operating Margin | -99.0% | — |
| Net Margin | -77.2% | 2991.2% |
| Revenue YoY | 94996.3% | — |
| Net Profit YoY | -15.1% | 506.9% |
| EPS (diluted) | $-0.13 | $4.70 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.2M | $1.9M | ||
| Q3 25 | $498.3K | $-220.0K | ||
| Q2 25 | $171.0K | $-284.0K | ||
| Q1 25 | — | $-371.0K | ||
| Q4 24 | — | $0 | ||
| Q3 24 | — | $0 | ||
| Q2 24 | $0 | $0 | ||
| Q1 24 | — | $0 |
| Q4 25 | $-957.9K | $57.7M | ||
| Q3 25 | $-1.0M | $-7.4M | ||
| Q2 25 | $-749.4K | $-9.5M | ||
| Q1 25 | — | $-11.0M | ||
| Q4 24 | — | $-14.2M | ||
| Q3 24 | — | $-17.6M | ||
| Q2 24 | $-809.2K | $-17.0M | ||
| Q1 24 | — | $1.0M |
| Q4 25 | -99.0% | — | ||
| Q3 25 | -263.9% | 3444.1% | ||
| Q2 25 | -574.8% | 3229.2% | ||
| Q1 25 | — | 3296.0% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -77.2% | 2991.2% | ||
| Q3 25 | -201.0% | 3358.6% | ||
| Q2 25 | -438.3% | 3341.2% | ||
| Q1 25 | — | 2973.3% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-0.13 | $4.70 | ||
| Q3 25 | $-0.14 | $-0.60 | ||
| Q2 25 | $-0.11 | $-0.78 | ||
| Q1 25 | — | $-0.90 | ||
| Q4 24 | — | $2.63 | ||
| Q3 24 | — | $-1.46 | ||
| Q2 24 | $-0.72 | $-1.42 | ||
| Q1 24 | — | $-6.33 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $840.5K | $48.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $13.1M | $42.0M |
| Total Assets | $13.4M | $61.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $840.5K | $48.3M | ||
| Q3 25 | — | $49.0M | ||
| Q2 25 | — | $54.8M | ||
| Q1 25 | — | $65.5M | ||
| Q4 24 | — | $78.0M | ||
| Q3 24 | — | $89.1M | ||
| Q2 24 | $4.5M | $97.7M | ||
| Q1 24 | — | $115.5M |
| Q4 25 | $13.1M | $42.0M | ||
| Q3 25 | $14.1M | $-18.4M | ||
| Q2 25 | $15.0M | $-12.2M | ||
| Q1 25 | — | $-4.0M | ||
| Q4 24 | — | $5.7M | ||
| Q3 24 | — | $18.3M | ||
| Q2 24 | $4.7M | $33.5M | ||
| Q1 24 | — | $48.8M |
| Q4 25 | $13.4M | $61.8M | ||
| Q3 25 | $14.3M | $57.8M | ||
| Q2 25 | $15.4M | $66.1M | ||
| Q1 25 | — | $79.1M | ||
| Q4 24 | — | $92.3M | ||
| Q3 24 | — | $104.5M | ||
| Q2 24 | $5.1M | $124.2M | ||
| Q1 24 | — | $152.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-733.1K | $-6.2M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | -0.11× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-733.1K | $-6.2M | ||
| Q3 25 | $-1.1M | $-4.2M | ||
| Q2 25 | $-716.9K | $-10.7M | ||
| Q1 25 | — | $-12.5M | ||
| Q4 24 | — | $-11.4M | ||
| Q3 24 | — | $-19.5M | ||
| Q2 24 | $-738.5K | $-22.2M | ||
| Q1 24 | — | $-14.6M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $-11.4M | ||
| Q3 24 | — | $-19.6M | ||
| Q2 24 | — | $-22.2M | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | -0.11× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -14.14× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
